Literature DB >> 21507517

Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Yasuyuki Fujita1, Naoya Yoshioka, Riichiro Abe, Junko Murata, Daichi Hoshina, Hirokatsu Mae, Hiroshi Shimizu.   

Abstract

BACKGROUND: Life-threatening adverse drug reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) sometimes start with clinical features of ordinary drug-induced skin reactions (ODSRs) and it may be difficult to make a correct diagnosis before severe mucocutaneous erosions occur. We have reported that serum granulysin levels are elevated (cut off: 10 ng/mL) in patients with SJS/TEN before generalized blisters form.
OBJECTIVE: We sought to develop a rapid detection system for elevated serum granulysin to predict the progression from ODSRs.
METHODS: Serum samples from 5 patients with SJS/TEN at 2 to 4 days before mucocutaneous erosions formed were analyzed. Sera from 24 patients with ODSRs and 31 healthy volunteers were also investigated as control subjects. We developed a rapid immunochromatographic assay for the detection of high levels of serum granulysin using two different antigranulysin monoclonal antibodies.
RESULTS: The immunochromatographic test showed positive results for 4 of 5 patients with SJS/TEN but only one patient of 24 with ODSRs. The results correlated closely with those of enzyme-linked immunosorbent assays. LIMITATIONS: The validation of the long-time stability in this test strip has not been investigated.
CONCLUSION: This novel test enables the prediction of SJS/TEN occurrence in patients even when only features of ODSRs are noted clinically.
Copyright © 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21507517     DOI: 10.1016/j.jaad.2010.04.042

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

Review 1.  In vitro testing for diagnosis of idiosyncratic adverse drug reactions: Implications for pathophysiology.

Authors:  Abdelbaset A Elzagallaai; Michael J Rieder
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

Review 2.  Drug-hypersensitivity syndrome: diagnosis and treatment.

Authors:  Rose L Hamm
Journal:  J Am Coll Clin Wound Spec       Date:  2012-06-23

Review 3.  Granulysin: killer lymphocyte safeguard against microbes.

Authors:  Farokh Dotiwala; Judy Lieberman
Journal:  Curr Opin Immunol       Date:  2019-05-18       Impact factor: 7.486

Review 4.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

5.  Cephalosporin-Induced Toxic Epidermal Necrolysis Treated with Intravenous Immunoglobulin.

Authors:  Konstantin Boroda; Li Li; Louis Riina; Shadab Ahmed
Journal:  Cureus       Date:  2015-10-21

Review 6.  Treatments for Severe Cutaneous Adverse Reactions.

Authors:  Yung-Tsu Cho; Chia-Yu Chu
Journal:  J Immunol Res       Date:  2017-12-27       Impact factor: 4.818

7.  Vancomycin-Induced Stevens-Johnson Syndrome in a Boy Under 2 Years Old: An Early Diagnosis by Granulysin Rapid Test.

Authors:  You-Cheng Lin; Ji-Nan Sheu; Wen-Hung Chung; Ren-You Pan; Chu-Ju Hung; Jen-Jung Cheng; Yu-Ping Hsiao
Journal:  Front Pediatr       Date:  2018-03-13       Impact factor: 3.418

8.  Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Lucia Liotti; Silvia Caimmi; Paolo Bottau; Roberto Bernardini; Fabio Cardinale; Francesca Saretta; Francesca Mori; Giuseppe Crisafulli; Fabrizio Franceschini; Carlo Caffarelli
Journal:  Acta Biomed       Date:  2019-01-29

9.  Toxic epidermal necrolysis in an 8-year-old girl successfully treated with cyclosporin A, intravenous immunoglobulin and plasma exchange.

Authors:  Marzena Zielińska; Łukasz Matusiak; Waldemar Gołębiowski; Katarzyna Swiątek; Iwona Chlebicka; Joanna Maj; Jacek Szepietowski
Journal:  Postepy Dermatol Alergol       Date:  2018-04-24       Impact factor: 1.837

10.  Management of Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis: Looking Beyond Guidelines!

Authors:  Rajesh Kumar; Anupam Das; Sudip Das
Journal:  Indian J Dermatol       Date:  2018 Mar-Apr       Impact factor: 1.494

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.